This company appeared on my screens today so I did some research including looking at the 10Q. The company IPOd 3 months ago. AGRX has a once-a-week birth control patch that is in a phase 3 trial. This product, Twirla, should be approved in the next 2 years and would result in sales of 200-400mil/year. This stock could easily double from it's current $130 million dollar market cap. Guru Investor Chuck Royce recently took a large position along with several other hedge fund investors according to the SEC filings (13d). There are lots of risks associated with this company. It has no current product and there is no guarantee it will receive approval or that it's product will capture much market share. There are several other companies with similar products. Twirla is unique in it's low dosing of hormones. This appears significant since other products have been pulled due to higher hormone levels causing problems. Twirla seems a good prospect. The 10Q states it might be available commercially by the end of 2016. Because of the size of this company, it would not take a large market share of the birth control patch market to make a significant price change in the stock. I think it's worth a small bet.